Evidence map›Paper›PMID 40426862›Full record

ArticleBiomedicines2025

Synergistic Anticancer Activity of HSP70 Inhibitor and Doxorubicin in Gain-of-Function Mutated p53 Breast Cancer Cells.

Kuan-Yo Wu, Ana Crucho, Mia Su, Sih-Tong Chen, Chen-Hsiu Hung, Yu-Ling Kou, Yu-Jie Liu, Tzu-Chi Hsu, Fang-Yu Yeh, Ching-Feng Lien and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kuan-Yo WuDepartment of Biomedical Engineering, I-Shou University, Kaohsiung City 82445, Taiwan.
Ana CruchoLisbon School of Medicine, Lisbon University, 1649-004 Lisboa, Portugal.
Mia SuFaculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Sih-Tong ChenDepartment of Medical Science and Biotechnology, I-Shou University, Kaohsiung City 82445, Taiwan.
Chen-Hsiu HungDepartment of Medical Laboratory Science, I-Shou University, Kaohsiung City 82445, Taiwan.
Yu-Ling KouDepartment of Medical Laboratory Science, I-Shou University, Kaohsiung City 82445, Taiwan.
Yu-Jie LiuDepartment of Medical Laboratory Science, I-Shou University, Kaohsiung City 82445, Taiwan.
Tzu-Chi HsuDepartment of Medical Laboratory Science, I-Shou University, Kaohsiung City 82445, Taiwan.
Fang-Yu YehSchool of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan.
Ching-Feng LienSchool of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan.ORCID 0000-0001-8245-5495
Chia-Chi ChenSchool of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan.ORCID 0000-0002-4905-3408
Bi-He CaiSchool of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan.ORCID 0000-0003-4226-6096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

aggregationapoptosisbreast cancerHSP70 inhibitorp53 mutation

Identifiers

PMID40426862
PMCPMC12109493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.